Rheumatology Billing & Coding Guide
Biologic infusions J-codes, joint injections 20600-20611, prior-auth burden for high-cost drugs.
Common Rheumatology CPT Codes
Ranked by claim frequency, with current MPFS work RVUs and global periods.
| Code | Description | Work RVU | Total RVU | Global |
|---|---|---|---|---|
| 20600 | Drain/inj joint/bursa w/o us | 0.64 | 1.68 | 000 |
| 20604 | Drain/inj joint/bursa w/us | 0.87 | 2.61 | 000 |
| 20605 | Drain/inj joint/bursa w/o us | 0.66 | 1.71 | 000 |
| 20606 | Drain/inj joint/bursa w/us | 0.98 | 2.82 | 000 |
| 20610 | Drain/inj joint/bursa w/o us | 0.77 | 2.06 | 000 |
| 20611 | Drain/inj joint/bursa w/us | 1.07 | 3.12 | 000 |
| 99213 | Office o/p est low 20 min | 1.30 | 2.85 | XXX |
| 99214 | Office o/p est mod 30 min | 1.92 | 4.06 | XXX |
| 99215 | Office o/p est hi 40 min | 2.80 | 5.76 | XXX |
| 86430 | Rheumatoid factor test qual | 0.00 | 0.00 | XXX |
| 86431 | Rheumatoid factor quant | 0.00 | 0.00 | XXX |
| 85025 | Complete cbc w/auto diff wbc | 0.00 | 0.00 | XXX |
| 86200 | Ccp antibody | 0.00 | 0.00 | XXX |
| 86038 | Antinuclear antibodies | 0.00 | 0.00 | XXX |
What Rheumatology practices are leaving on the table
High-value services that consistently get under-billed across the specialty. Each one is rooted in current 2026 fee schedule and policy updates.
Ultrasound-guided injections (20604/20606) billed instead of non-guided (20600/20610) on 40-50% of claims. Impact: 0.23-0.31 RVU difference per injection = $9-12 per claim at MAC rates. Workflow: Train clinical staff to document US guidance at point of care; audit EHR templates to require 'US guidance: yes/no' checkbox before note sign-off.
Modifier 25 for distinct E/M not captured on joint injection same-day visits. Impact: Average 99213 = $45-65 per claim, lost on 30-40% of eligible visits. Workflow: Build standing order in EHR to prompt provider: 'Was E/M separate from injection? If yes, append -25 to E/M code.' Flag visits with E/M and injection same day for modifier review before batch submission.
Bilateral joint injections (knees, shoulders) billed as unilateral only. Impact: Missed revenue of 20% of RVUs on bilateral cases = $18-25 per claim. Workflow: Audit operative notes for bilateral anatomy mention; retrain providers to document left AND right explicitly if both injected. Query provider on historical claims lacking bilateral documentation.
Lab panel fragmentation: RF qualitative (86430) billed alone when quantitative (86431) clinically indicated. Impact: Missed 86431 code at $12-18 per claim on 25% of RF orders. Workflow: Add reflex protocol to EHR: 'If RF qual positive, order RF quant same day.' Educate providers that payer policy permits quant without manual intervention if clinical note documents need.
Code pairs that auto-bundle to CO-97
From the National Correct Coding Initiative for Rheumatology. The rationale tells you when a modifier legitimately bypasses the edit and when it cannot.
Both are ultrasound-guided joint injections. These bundle when performed on the same joint at the same session. Modifier 59 or XS is not appropriate. Bill only the larger work RVU code (20606) unless distinct anatomical structures are documented (separate knee vs ankle). Documentation must specify separate joint locations with separate clinical indications.
Both are ANA tests with different methodologies. Medicare bundles these when ordered on the same date. If both are medically necessary (e.g., reflex ANA with titer), append modifier 91 (repeat clinical laboratory procedure) or verify payer policy explicitly allows both. Chart must document clinical reason for both on same encounter.
Qualitative and quantitative rheumatoid factor. These bundle together. Order both only if clinical decision-making explicitly documents need for quantitative follow-up same day (e.g., monitoring biologics response). Modifier 91 may apply for repeat same-day testing, not 59. Most denials cite medically unnecessary duplicate testing.
Office visit and injection on same day. Modifier 25 applies only if visit is distinct and separately identifiable. If visit is just pre-procedure briefing or post-injection observation, do not bill 99213. Documentation must show separate history, exam, and medical decision-making unrelated to injection alone.
Modifier Guidance for Rheumatology
When each modifier legitimately applies in this specialty, with denial-pattern context and audit-defense documentation.
Used when office visit (99213-99215) is substantial and separate from the joint injection procedure on the same day. Example: Patient with new lupus diagnosis presents for lab review and disease management counseling (99214), then receives steroid injection in different joint to manage acute flare. Chart must document separate encounter elements before or after procedure. Without distinct documentation, auditors bundle the visit into global zero-day global period of injection.
Distinct procedural service. In Rheumatology, applies when bilateral joint injections (both knees vs left knee and right shoulder) are performed at same session. Do not use for lab testing repeats. Do not use to separate ANA from RF on same day. Requires separate incision, exposure, or anatomically distinct area. NCCI manual prohibits 59 for bilateral injections; use modifier 50 instead if payer allows.
Bilateral procedure. When both knees or both shoulders are injected at same session, some payers accept 50 instead of 59 or instead of coding left and right separately. Check payer manual. Medicare typically bundles bilateral injections under single code without modifier. Most Rheumatology practices do not use 50; instead code LT and RT separately per payer instruction.
Physical therapy plan of care modifier. Rheumatology does not typically report this. If Rheumatologist co-manages patient receiving PT alongside biologic therapy, do not append GP to E/M; only PT provider uses GP. Misapplication causes claim denials with interpretation that physician services were PT delivery.
Requirements specified in medical policy have been met. Used for Medicare prior authorization verification or policy compliance markers. In Rheumatology, apply KX to injectable biologics claims when LCD criteria are documented (e.g., failed DMARD trial for RA before TNF inhibitor). Chart must include evidence of prior treatment and failure documentation.
Documentation requirements
What needs to live in the encounter note for these codes to survive a payer audit.
- Joint location, side (left/right), and size documented in procedure note. Auditors deny injections lacking specific anatomy, as they cannot verify medical necessity or bilateral vs unilateral billing.
- Pre-injection assessment including baseline pain score, swelling grade, and functional limitation for that specific joint. Establishes medical necessity and allows defense against overutilization audits.
- Medication(s) injected with concentration, volume, and lot number. Supports billing for specific joint injection code and defends against unbundling denials.
- Ultrasound image confirmation (if 20604/20606) with documentation that probe placement verified needle position in joint space. Distinguishes ultrasound-guided from non-guided and justifies higher RVU code.
- Post-injection response plan including patient education, activity restrictions, and follow-up timeframe. Required for global period defense; shows physician management of post-injection period.
- Indication for E/M service (if billed with modifier 25) that is separate from injection reason. Example: 'Patient presents with RA flare in bilateral knees and new morning stiffness concerning for disease progression; reviewed labs and escalated DMARD.' Without this, auditor bundles E/M into injection global.
OIG and audit triggers in Rheumatology
Patterns that show up in OIG Work Plans, RAC audits, and CERT improper payment reviews. Build internal compliance checks around these.
RAC Pattern: Unbundling E/M with injection when documentation shows visit is solely pre-procedure. Finding: Auditor denies 99213 as bundled into global period of 20604. Defense requires separate chart note with distinct MDM (e.g., medication adjustment, disease progression assessment) documented before or after injection, not integrated into procedure note.
OIG Work Plan 2024-2026: Overutilization of joint injections in RA patients on biologics. Finding: Claims for 6+ injections per year per patient flagged. Auditor requests clinical notes showing disease assessment justifying frequency. Defense requires documentation of failed biologic, specific joint refractory to systemic therapy, or documented imaging findings (MRI/ultrasound) of persistent inflammation.
NCCI Edit Audit: Modifier 59 appended to bilateral injection codes (20600-59 and 20600 same claim). Finding: Auditor denies both as duplicative; NCCI does not allow 59 to separate bilateral procedures. Defense: Recode using separate LT/RT modifiers per payer guidance, or bill single code with 50 modifier per MAC LCD (varies by region).
Commercial Payer Medical Policy Denial: CCP and RF ordered same day in established RA patient already on TNF inhibitor. Finding: Payer denies RF as medically unnecessary when CCP already performed. Defense requires chart note documenting specific clinical question answered by quantitative RF (e.g., monitoring for autoimmune flare or medication toxicity differential). Without separate indication, rework as single RF code.
Payer-specific billing notes
Where the major payers diverge from generic Medicare rules in Rheumatology.
ME Medicare +
LCD varies by MAC region; most MACs bundle non-guided and guided injections under single code without modifier separation. Prior authorization not required for injections under $500 aggregate per year per joint per CMS guidance (2026 update). Review your regional MAC LCD before billing bilateral injections; some regions allow LT/RT modifiers, others require separate claims. E/M with modifier 25 requires documented separate service in separate note or distinct time block; same-visit notes risk bundling denial. Lab testing (ANA, RF, CCP) covered without prior auth if ordered for initial RA workup; repeat testing same day requires medical record justification.
UN UnitedHealthcare +
Optum delegates Rheumatology medical policies to regional Blues plans in most states. Prior authorization required for biologic therapy initiation but not for office visits or injections under $300 per claim. Bilateral injections require separate codes with LT/RT modifiers, not 50 modifier. Lab testing covered without prior auth; duplicate same-day testing (e.g., ANA qualitative and quantitative) denied unless clinical note documents reflex testing or therapeutic drug monitoring. UHC medical policy allows E/M with injection modifier 25 if visit time documented separately (not bundled into procedure time).
AN Anthem +
Anthem uses medical policy medical necessity criteria for Rheumatology similar to Medicare LCDs but may be more restrictive on injection frequency. Prior authorization required for injections if patient already received 4+ injections same joint within 12 months (overutilization flag). Lab tests (RF, CCP, ANA) covered; bundling rules follow NCCI with Anthem-specific edits that may bundle related tests (e.g., RF qual and quant) without modifier override. Modifier 25 requires separate documentation; Anthem denies E/M if procedure note shows integrated pre/post-procedure assessment.
CI Cigna +
Cigna eviCore radiology delegation does not include Rheumatology ultrasound-guided injections; in-office guidance does not require prior auth. Lab testing covered without prior auth; Cigna follows NCCI bundling with rare exceptions for clinically supported repeat testing. Bilateral injections coded with 50 modifier on single line item per Cigna manual (differs from other payers). E/M with 25 modifier allowed if documented in separate encounter; Cigna audits E/M bundling rates more aggressively than Medicare in RA cohorts.
Standard Rheumatology coding workflow
Step 1: Extract indication from chief complaint and prior imaging/labs to confirm joint-specific diagnosis and medical necessity. Step 2: Review procedure note for documented joint location, side (LT/RT), and size; if missing, query provider before submission. Step 3: Check ultrasound guidance notation and image count; if documented, bill 20604/20606 (higher RVU); if not, bill 20600/20605/20610. Step 4: If E/M bill same day, verify visit note contains separate history/exam/MDM unrelated to procedure; if only pre/post-injection notes, do not append modifier 25. Step 5: Verify lab testing for ANA, RF, CCP not duplicated same day; if clinically necessary, use modifier 91 or contact payer for approval.
Get the full PayerReady toolkit
Credentialing + billing/coding tools built for Rheumatology, free access with enrollment.
Start free →Run this code through our claim audit tool
Check NCCI bundling, MUE limits, and modifier logic before submission.
Try the auditor →Verified against CMS 2026 code set, current NCCI Quarterly Updates, and the X12 Claim Adjustment Reason Code reference. Last updated April 15, 2026. See data sources and methodology.
Did this page help?
Quick signal so we know what to improve.
If you want a code reference page that doesn't exist yet, email coding@payerready.com.
Tell us what's missing or wrong: coding@payerready.com. We respond within 5 business days.
Reviewed by the PayerReady Medical Coding Team
Verified against the CMS 2026 code set on May 31, 2026.
Powered by 11K CPT · 98K ICD-10 · 860K MPFS rates · 4.5M NCCI edits · 9.5M NPIs. Our data methodology · About our coding team